Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.

Lupus science & medicine

de Groot KA, Tsang A Sjoe M, Niewerth D, Cloos J, Blank JL, Niessen HW, Zweegman S, Voskuyl AE, Jansen G, van der Heijden JW.
PMID: 26719810
Lupus Sci Med. 2015 Dec 18;2(1):e000121. doi: 10.1136/lupus-2015-000121. eCollection 2015.

OBJECTIVE: To describe the pharmacodynamic monitoring of (immuno)proteasome inhibition following treatment with bortezomib in a therapy-refractory systemic lupus erythematosus (SLE) patient with life-threatening myocarditis and lupus nephritis.PATIENT AND METHODS: Inhibition of catalytic activities of the proteasome subunits β5 (constitutive...

Cite
de Groot KA, Tsang A Sjoe M, Niewerth D, et al. Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis. Lupus Sci Med. 2015;2(1):e000121doi: 10.1136/lupus-2015-000121.
de Groot, K. A., Tsang A Sjoe, M., Niewerth, D., Cloos, J., Blank, J. L., Niessen, H. W., Zweegman, S., Voskuyl, A. E., Jansen, G., & van der Heijden, J. W. (2015). Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis. Lupus science & medicine, 2(1), e000121. https://doi.org/10.1136/lupus-2015-000121
de Groot, Karina A, et al. "Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis." Lupus science & medicine vol. 2,1 (2015): e000121. doi: https://doi.org/10.1136/lupus-2015-000121
de Groot KA, Tsang A Sjoe M, Niewerth D, Cloos J, Blank JL, Niessen HW, Zweegman S, Voskuyl AE, Jansen G, van der Heijden JW. Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis. Lupus Sci Med. 2015 Dec 18;2(1):e000121. doi: 10.1136/lupus-2015-000121. eCollection 2015. PMID: 26719810; PMCID: PMC4691954.
Copy Download .nbib Format: NLM
Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal.

Clinical kidney journal

Duineveld C, Bouwmeester R, van der Heijden JW, Berger SP, van de Kar NCAJ, Wetzels JFM.
PMID: 34631043
Clin Kidney J. 2020 Dec 15;14(8):1939-1945. doi: 10.1093/ckj/sfaa241. eCollection 2021 Aug.

BACKGROUND: The introduction of eculizumab has significantly improved the outcome of patients with atypical haemolytic uraemic syndrome (aHUS). Because of the risk of relapse after discontinuation, eculizumab was proposed as life-long therapy. However, data on the outcome of relapse...

Cite
Duineveld C, Bouwmeester R, van der Heijden JW, et al. Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. Clin Kidney J. 2020;14(8):1939-1945doi: 10.1093/ckj/sfaa241.
Duineveld, C., Bouwmeester, R., van der Heijden, J. W., Berger, S. P., van de Kar, N. C. A. J., Wetzels, J. F. M. (2021). Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. Clinical kidney journal, 14(8), 1939-1945. https://doi.org/10.1093/ckj/sfaa241
Duineveld, Caroline, et al. "Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal." Clinical kidney journal vol. 14,8 (2021): 1939-1945. doi: https://doi.org/10.1093/ckj/sfaa241
Duineveld C, Bouwmeester R, van der Heijden JW, Berger SP, van de Kar NCAJ, Wetzels JFM. Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. Clin Kidney J. 2020 Dec 15;14(8):1939-1945. doi: 10.1093/ckj/sfaa241. eCollection 2021 Aug. PMID: 34631043; PMCID: PMC8496203.
Copy Download .nbib Format: NLM
A Randomized Comparison of two Short Intensive Chemotherapy Regimens in Children and Young Adults With Osteosarcoma: Results in Patients With Metastases: A Study of the European Osteosarcoma Intergroup.

Sarcoma

Bramwell VH, Burgers MV, Souhami RL, Taminiau AH, Van Der Eijken JW, Craft AW, Malcolm AJ, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM.
PMID: 18521218
Sarcoma. 1997;1(3):155-60. doi: 10.1080/13577149778245.

Purpose. To report the outcome of 37 patients with metastatic osteosarcoma entered into a large randomized trial (EOI 80831/MRC B002) comparing two different regimens of chemotherapy in patients with osteosarcoma.Methods. Patients with biopsy-proven osteosarcoma localized and metastatic, age 40...

Cite
Bramwell VH, Burgers MV, Souhami RL, et al. A Randomized Comparison of two Short Intensive Chemotherapy Regimens in Children and Young Adults With Osteosarcoma: Results in Patients With Metastases: A Study of the European Osteosarcoma Intergroup. Sarcoma. 1997;1(3):155-60doi: 10.1080/13577149778245.
Bramwell, V. H., Burgers, M. V., Souhami, R. L., Taminiau, A. H., Van Der Eijken, J. W., Craft, A. W., Malcolm, A. J., Uscinska, B., Kirkpatrick, A. L., Machin, D., & Van Glabbeke, M. M. (1997). A Randomized Comparison of two Short Intensive Chemotherapy Regimens in Children and Young Adults With Osteosarcoma: Results in Patients With Metastases: A Study of the European Osteosarcoma Intergroup. Sarcoma, 1(3), 155-60. https://doi.org/10.1080/13577149778245
Bramwell, V H, et al. "A Randomized Comparison of two Short Intensive Chemotherapy Regimens in Children and Young Adults With Osteosarcoma: Results in Patients With Metastases: A Study of the European Osteosarcoma Intergroup." Sarcoma vol. 1,3 (1997): 155-60. doi: https://doi.org/10.1080/13577149778245
Bramwell VH, Burgers MV, Souhami RL, Taminiau AH, Van Der Eijken JW, Craft AW, Malcolm AJ, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM. A Randomized Comparison of two Short Intensive Chemotherapy Regimens in Children and Young Adults With Osteosarcoma: Results in Patients With Metastases: A Study of the European Osteosarcoma Intergroup. Sarcoma. 1997;1(3):155-60. doi: 10.1080/13577149778245. PMID: 18521218; PMCID: PMC2395371.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries